2.Effect of Danggui Shaoyaosan on TLR4/MyD88/JNK Signaling Pathway on Rats with Nonalcoholic Fatty Liver Disease
Yi-shui LI ; Xin-qiao CHU ; Ya-ning BIAO ; Mu-qing ZHANG ; Yi-lu HAN ; Zi-xuan LI ; Yi-xin ZHANG
Chinese Journal of Experimental Traditional Medical Formulae 2021;27(17):24-31
Objective:To explore
3.Transcriptional profiling and network pharmacology analysis identify the potential biomarkers from Chinese herbal formula Huosu Yangwei Formula treated gastric cancer in vivo.
Sheng-Quan FANG ; Yue-Han LIU ; Kun-Peng ZHAO ; Hui-Xing ZHANG ; Hong-Wei WANG ; Yu-Hai DENG ; Yu-Xuan ZHOU ; Guang-Bo GE ; Hong-Mei NI ; Qi-Long CHEN
Chinese Journal of Natural Medicines (English Ed.) 2021;19(12):944-953
Huosu Yangwei (HSYW) Formula is a traditioanl Chinese herbal medicine that has been extensively used to treat chronic atrophic gastritis, precancerous lesions of gastric cancer and advanced gastric cancer. However, the effective compounds of HSYW and its related anti-tumor mechanisms are not completely understood. In the current study, 160 ingredients of HSYW were identified and 64 effective compounds were screened by the ADMET evaluation. Furthermore, 64 effective compounds and 2579 potential targets were mapped based on public databases. Animal experiments demonstrated that HSYW significantly inhibited tumor growth in vivo. Transcriptional profiles revealed that 81 mRNAs were differentially expressed in HSYW-treated N87-bearing Balb/c mice. Network pharmacology and PPI network showed that 12 core genes acted as potential markers to evaluate the curative effects of HSYW. Bioinformatics and qRT-PCR results suggested that HSYW might regulate the mRNA expression of DNAJB4, CALD, AKR1C1, CST1, CASP1, PREX1, SOCS3 and PRDM1 against tumor growth in N87-bearing Balb/c mice.
Animals
;
Biomarkers
;
China
;
Drugs, Chinese Herbal
;
Mice
;
Network Pharmacology
;
Stomach Neoplasms/genetics*
4.Effect of breastfeeding on the development of infection-related diseases during hospitalization in late preterm infants in 25 hospitals in Beijing, China.
Lu-Yan HAN ; Xiao-Jing XU ; Xiao-Mei TONG ; Xin ZHANG ; Jie LIU ; Li YANG ; Hui LIU ; Ju YAN ; Zhi-Fang SONG ; Ya-Bo MEI ; Rong MI ; Xuan-Guang QIN ; Yu-Huan LIU ; Yu-Jie QI ; Wei ZHANG ; Hui-Hui ZENG ; Hong CUI ; Hui LONG ; Guo GUO ; Xu-Lin CHEN ; Zhao-Yi YANG ; Fang SUN ; Xiao-Hui FU ; Chang-Yan WANG ; Zheng-Hong LI
Chinese Journal of Contemporary Pediatrics 2020;22(12):1245-1250
OBJECTIVE:
To investigate the incidence rate of infectious diseases during hospitalization in late preterm infants in Beijing, China, as well as the risk factors for infectious diseases and the effect of breastfeeding on the development of infectious diseases.
METHODS:
Related data were collected from the late preterm infants who were hospitalized in the neonatal wards of 25 hospitals in Beijing, China, from October 23, 2015 to October 30, 2017. According to the feeding pattern, they were divided into a breastfeeding group and a formula feeding group. The two groups were compared in terms of general status and incidence rate of infectious diseases. A multivariate logistic regression analysis was used to investigate the risk factors for infectious diseases.
RESULTS:
A total of 1 576 late preterm infants were enrolled, with 153 infants in the breastfeeding group and 1 423 in the formula feeding group. Of all infants, 484 (30.71%) experienced infectious diseases. The breastfeeding group had a significantly lower incidence rate of infectious diseases than the formula feeding group (22.88% vs 31.55%,
CONCLUSIONS
Breastfeeding can significantly reduce the incidence of infectious diseases and is a protective factor against infectious diseases in late preterm infants. Breastfeeding should therefore be actively promoted for late preterm infants during hospitalization.
Beijing/epidemiology*
;
Breast Feeding
;
China/epidemiology*
;
Communicable Diseases/epidemiology*
;
Female
;
Hospitalization
;
Hospitals
;
Humans
;
Incidence
;
Infant
;
Infant, Newborn
;
Infant, Premature
;
Male
;
Pregnancy
5.Clinical safety of short-term antivirus intervention in 54 pregnant women with high viral load of hepatitis B e antigen and the effect of blocking mother-to-child transmission of hepatitis B virus
Qingwei GAO ; Peng GAO ; Nan DING ; Xuan LI ; Xin LIU ; Guang HAN ; Aijun SUN
Chinese Journal of Postgraduates of Medicine 2019;42(7):649-653
Objective To investigate the effects and safety of short-term telbivudine intervention on blocking mother-to-child transmission (MTCT) of hepatitis B virus (HBV) in pregnant women with hepatitis B e antigens (HBeAg) positive during mid-gestation. Methods Fifty-four chronic HBV infection pregnant women with HBeAg positive from November 2016 to November 2017 in Dalian Sixth People′s Hospital Affiliated to Dalian Medical University were selected, and the serum HBV DNA (logarithmic transformation) of pregnant women was ≥1010 U/L. The pregnant women began oral telbivudine 600 mg at the 24th week of pregnancy, 1 time/d, and stopped at the day of delivery. The neonates were injected 10 μg hepatitis B vaccine and 100 U HBV immunoglobin 12 h after parturition, and they were injected 10 μg hepatitis B vaccine at 1 and 6 months of birth. The HBV DNA, creatine kinase (CK), alanine aminotransferase (ALT) and total bilirubin (TBIL) at 12th, 24th, 28th, 32th week of pregnancy and 1, 7 months after parturition were detected. The hepatitis B surface antibody (HBsAb) and hepatitis B surface antigen (HBsAg) of infants during 28 to 32 weeks of birth were detected. Results There were no statistical differences in CK, ALT and TBIL of 54 pregnant women (P>0.05). The HBV DNA at 28th, 32th week of pregnancy and 1 month after parturition was significantly lower than that at 12th week of pregnancy (5.7 ± 2.2, 5.1 ± 2.3 and 8.3 ± 1.7 vs. 9.5 ± 1.0), and there was statistical difference (P<0.05); there was no statistical difference between 7 months and 12th week of pregnancy after parturition (P>0.05). During 28 to 30 weeks of birth, all the neonates showed serum HBsAb>109 U/L and HBsAg < 30 U/L. Conclusions Short-term intervention with telbivudine in mid-gestation for pregnant women infected with HBV could significantly reduce the level of serum HBV-DNA to the safety level or below. The adverse effects are not found during the telbivudine intervention period. Of note, after drug withdrawal, the HBV DNA level will rebound variously. The virus related detection conducted on the neonates indicates that short-term telbivudine intervention can realize complete MTCT blocking.
6.Multi-center Study of Enteral Feeding Practices in Hospitalized Late Preterm Infants in China.
Mei Ying QUAN ; Zheng Hong LI ; Dan Hua WANG ; Kurt SCHIBLER ; Li YANG ; Jie LIU ; Xuan Guang QIN ; Xin ZHANG ; Tong Yan HAN ; Wei ZHANG
Biomedical and Environmental Sciences 2018;31(7):489-498
OBJECTIVETo investigate the current enteral feeding practices in hospitalized late preterm infants in the Beijing area of China.
METHODSA multi-center, cross-sectional study was conducted. Infants born after 34 weeks and before 37 weeks of gestation were enrolled from 25 hospitals in the Beijing area of China from October 2015 to October 2017. Data on enteral feeding practices were collected and analyzed.
RESULTSA total of 1,463 late preterm infants were enrolled, with a mean gestational age (GA) of 35.6 (34.9, 36.1) weeks. The percentage of exclusive breastfeeding was 4.5% at the initiation of enteral feeding but increased to 14.4% at discharge. When human milk was not available, most infants (46.1%) were fed with preterm infant formula. The rate of exclusive human milk feeding in infants born at 34 weeks gestation was higher than at discharge (21.1% of infants born at 34 weeks' GA versus 12.1% of infants born at 35 weeks' GA versus 12.3% of infants born at 36 weeks' GA, P < 0.001). Only 28.4% of late preterm infants achieved full enteral feeding at discharge, and only 19.2% achieved 120 kcal/(kg•d) by enteral feeding at discharge. Importantly, 40.5% of infants did not regain the birth weight at discharge.
CONCLUSIONEnteral feeding support of late preterm infants has not been standardized to achieve optimal growth. Moreover, the human milk feeding rate was low, and many late preterm infants did not achieve the goal of enteral feeding and failed to regain birth weight at the time of discharge. More aggressive enteral feedings protocols are needed to promote human milk feeding and optimize growth for late preterm infants.
Breast Feeding ; China ; Cross-Sectional Studies ; Enteral Nutrition ; Female ; Gestational Age ; Humans ; Infant Formula ; Infant, Newborn ; Infant, Premature ; Male ; Milk, Human
7.Clinical observation of standard IA regimen as induction chemotherapy in 242 patients with newly diagnosed acute myeloid leukemia.
Jia Yu HUANG ; Wei Xing LIU ; Yun LIAN ; Hui Hui ZHAO ; Han Xin WU ; Hua LU ; Li Juan CHEN ; Guang Sheng HE ; Jian Yong LI ; Si Xuan QIAN
Chinese Journal of Hematology 2018;39(4):331-335
8.Detection and clinical features of MLL gene rearrangement in adult patients with acute leukemia.
Ping LIU ; Run ZHANG ; Zheng GE ; Zhong-Kun LIN ; Juan LIU ; Si-Xuan QIAN ; Su-Jiang ZHANG ; Hua LU ; Han-Xin WU ; Hong-Xia QIU ; Peng LIU ; Wei XU ; Li-Juan CHEN ; Chao LU ; Bin-Bin LU ; Chun QIAO ; Hai-Rong QIU ; Guang-Rong ZHU ; Jian-Fu ZHANG ; Yu-Jie WU ; Jian-Yong LI
Journal of Experimental Hematology 2012;20(5):1110-1116
This study was purposed to investigate the incidence of mixed lineage leukemia (MLL) gene rearrangement and partner gene types as well as the clinical features and prognosis of acute leukemia (AL) with this rearrangement through detection in adult AL using combination of 3 techniques, and to evaluate the clinical value of this combination detection. The MLL gene rearrangement in 183 cases of adult AL was detected by combination of conventional cytogenetics, split signal FISH and multiplex nested PCR. The results showed that the incidence of MLL rearrangements in adult patients with AL was low (8.2%), and MLL-AF4 fusion gene was most common and predominant in acute lymphoblastic leukemia (ALL), while the MLL-AF6 and MLL-AF9 were most frequent in acute myeloid leukemia (AML). Extramedullary involvements were found in 40% of MLL-rearranged AL patients, and 33.3% of patients with MLL-rearranged AL reached to complete remission within 30 days during induction chemotherapy. In addition, in this cohort of MLL-rearranged adult AL patients, the 3-month relapse rate and 6-month overall survival rate were 50.0% and 50.0% respectively. It is concluded that the rate of missed diagnosis of CC technique for patients with MLL-rearranged AL reached to 60% in this study, while the combination of CC, FISH and multiplex nested PCR has been confirmed to have important significance for evaluating prognosis and conducting clinical therapy of patients with MLL-rearranged AL.
Adolescent
;
Adult
;
Aged
;
Female
;
Gene Rearrangement
;
Humans
;
Leukemia, Myeloid, Acute
;
genetics
;
Male
;
Middle Aged
;
Myeloid-Lymphoid Leukemia Protein
;
genetics
;
Oncogene Proteins, Fusion
;
genetics
;
Young Adult
9.The efficacy and safety of risperidone long-acting injectable for the treatment of schizophrenia
Jiong LUO ; Xin MA ; Sheng-mei MU ; Chang-jie NIE ; Meng FAN ; Yun-long TAN ; Yi CAO ; Fu-sheng QI ; Wei-ning HE ; Hong-hui CHEN ; Jiao-ping WANG ; Zhi-min XUE ; Jing-xuan ZHANG ; Aa-min GAO ; Guo-zhen YUAN ; Yun-xing YAN ; Shao-ping ZHANG ; Han-qing YANG ; Li KUANG ; Wei TANG ; Chong-guang LI ; Hui-zhong QIAN ; Bi FENG ; Gang WANG
Chinese Journal of Psychiatry 2010;43(1):14-18
Objective To evaluate the efficacy and safety of risperidone long-acting injectable (LAIR) for the treatment of schizophrenia in a large sample size in Chinese population.Methods This was an open-label, multi-center and prospective study in naturalistic treatment.Patients suffering from schizophrenia and schizoaffective disorder according to the Diagnostic and Statistical Manual of Mental Disorders-IV diagnostic criteria were treated with LAIR for 12 weeks, every two weeks a time.The PANSS total score, positive and negative symptom scores, Clinical Global Impressions-Severity and Clinical Global Impressions-Improvement were evaluated at baseline, and the 4th, 6th, 8th, 12th week treatment respectively.The adverse events were recorded.Results Altogether 251 patients from 17 hospitals across China were enrolled in the study.From the end of 4th week to the end of 12th week, the PANSS total score,positive and negative symptom scores, general psychopathology score significantly decreased compared with the baseline score (P<0.01).The effective rate, improvement rate and the percentage of patients who met the criteria of clinical relief were 57.4%, 79.9% and 76.6%, respectively.At the end of 4th week, the better decline level on PANSS score were in patients with illness duration of 2 years or shorter than that in ones with duration of longer than 2 year, and this trend persisted into the end of treatment.The total adverse events rate was 12.4%, and most were mild and moderate.Conclusions LAIR is effective and safe for treatment of schizophrenia and schizoaffective disorder, with better effect in patients with shorter illness duration.
10.The efficacy and safety of risperidone long-acting injectable for the treatment of schizophrenia
Jiong LUO ; Xin MA ; Sheng-mei MU ; Chang-jie NIE ; Meng FAN ; Yun-long TAN ; Yi CAO ; Fu-sheng QI ; Wei-ning HE ; Hong-hui CHEN ; Jiao-ping WANG ; Zhi-min XUE ; Jing-xuan ZHANG ; Aa-min GAO ; Guo-zhen YUAN ; Yun-xing YAN ; Shao-ping ZHANG ; Han-qing YANG ; Li KUANG ; Wei TANG ; Chong-guang LI ; Hui-zhong QIAN ; Bi FENG ; Gang WANG
Chinese Journal of Psychiatry 2010;43(1):14-18
Objective To evaluate the efficacy and safety of risperidone long-acting injectable (LAIR) for the treatment of schizophrenia in a large sample size in Chinese population.Methods This was an open-label, multi-center and prospective study in naturalistic treatment.Patients suffering from schizophrenia and schizoaffective disorder according to the Diagnostic and Statistical Manual of Mental Disorders-IV diagnostic criteria were treated with LAIR for 12 weeks, every two weeks a time.The PANSS total score, positive and negative symptom scores, Clinical Global Impressions-Severity and Clinical Global Impressions-Improvement were evaluated at baseline, and the 4th, 6th, 8th, 12th week treatment respectively.The adverse events were recorded.Results Altogether 251 patients from 17 hospitals across China were enrolled in the study.From the end of 4th week to the end of 12th week, the PANSS total score,positive and negative symptom scores, general psychopathology score significantly decreased compared with the baseline score (P<0.01).The effective rate, improvement rate and the percentage of patients who met the criteria of clinical relief were 57.4%, 79.9% and 76.6%, respectively.At the end of 4th week, the better decline level on PANSS score were in patients with illness duration of 2 years or shorter than that in ones with duration of longer than 2 year, and this trend persisted into the end of treatment.The total adverse events rate was 12.4%, and most were mild and moderate.Conclusions LAIR is effective and safe for treatment of schizophrenia and schizoaffective disorder, with better effect in patients with shorter illness duration.

Result Analysis
Print
Save
E-mail